TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07624305: A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2800 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,890,264

Rescue Site Savings

+$7,165,888

Unlock Full NCT07624305 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07624305 Rescue Dossier →